Siegfried Holding AG (0QQO.L)

CHF 978.56

(0.57%)

EBITDA Summary of Siegfried Holding AG

  • Siegfried Holding AG's latest annual EBITDA in 2023 was 241.21 Million CHF , down -23.24% from previous year.
  • Siegfried Holding AG's latest quarterly EBITDA in 2024 Q2 was 130.7 Million CHF , down 0.0% from previous quarter.
  • Siegfried Holding AG reported an annual EBITDA of 308.29 Million CHF in 2022, up 45.24% from previous year.
  • Siegfried Holding AG reported an annual EBITDA of 213.53 Million CHF in 2021, up 60.65% from previous year.
  • Siegfried Holding AG reported a quarterly EBITDA of 113.88 Million CHF for 2023 Q2, down 0.0% from previous quarter.
  • Siegfried Holding AG reported a quarterly EBITDA of N/A for 2023 FY, down -23.24% from previous quarter.

Annual EBITDA Chart of Siegfried Holding AG (2023 - 2002)

Historical Annual EBITDA of Siegfried Holding AG (2023 - 2002)

Year EBITDA EBITDA Growth
2023 241.21 Million CHF -23.24%
2022 308.29 Million CHF 45.24%
2021 213.53 Million CHF 60.65%
2020 132.17 Million CHF 24.43%
2019 106.17 Million CHF -15.8%
2018 126.63 Million CHF 14.38%
2017 110.71 Million CHF 23.27%
2016 92.53 Million CHF 20.77%
2015 74.37 Million CHF 45.48%
2014 51.12 Million CHF -10.69%
2013 57.23 Million CHF 43.22%
2012 44.86 Million CHF -3.49%
2011 37.26 Million CHF 7.85%
2010 30.24 Million CHF 74.72%
2009 33.83 Million CHF -85.13%
2008 147.81 Million CHF 170.36%
2007 69.86 Million CHF -18.09%
2006 68.56 Million CHF -20.86%
2005 84.34 Million CHF 44.93%
2004 62.01 Million CHF -38.3%
2003 94.31 Million CHF -7.47%
2002 101.93 Million CHF 0.0%

Peer EBITDA Comparison of Siegfried Holding AG

Name EBITDA EBITDA Difference
Relief Therapeutics Holding AG -108.2 Million CHF 322.933%
Tecan Group AG 205.57 Million CHF -17.339%
Santhera Pharmaceuticals Holding AG 79.17 Million CHF -204.668%
Basilea Pharmaceutica AG 29.49 Million CHF -717.827%
Bachem Holding AG 163.27 Million CHF -47.736%
Molecular Partners AG -59.51 Million CHF 505.306%